Immunotherapy of cancer using interleukin 2: current status and future prospects

Steven A. Rosenberg

Research output: Contribution to journalReview articlepeer-review


Lymphokine-activated killer (LAK) cells can be isolated as tumor-specific killer cells from a tumor-bearing host, after selective expansion in vitro by culture in interleukin 2 (IL-2). Animal experiments as well as clinical trials have shown that the adoptive transfer of these MHC unrestricted killer cells into tumor bearing hosts can cause the regression of cancer in selected patients. Here, Steven Rosenberg details his group's work on LAK cell therapy, and suggests how the clinical benefits gained so far can be improved upon.

Original languageEnglish (US)
Pages (from-to)63
Number of pages1
JournalTrends in Immunology
Issue number1-12
StatePublished - 1988
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Immunotherapy of cancer using interleukin 2: current status and future prospects'. Together they form a unique fingerprint.

Cite this